Board of Directors
Tim McCarthy (Executive Chairman)
Tim joined Incanthera in March 2014. He has more than 35 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors. He is also the Non-executive Chairman of ImmuPharma plc, an AIM-quoted specialist drug discovery and development company, and a Supervisory Board member of 4basebio AG, an international molecular biology products company listed on the Prime Standard segment of the Frankfurt Stock Exchange. He is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.
Dr Simon Ward (Chief Executive Officer)
Simon was instrumental in establishing Incanthera in March 2010 as a vehicle to commercialise and seek development funding for the intellectual property being created by the ICT. In 2000, he founded and was appointed chief executive of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases which in 2005 was acquired by York Pharma plc, an AIM-quoted pharmaceutical company focused on the field of dermatology. From 2005 to 2009, he held a non-board position as Chief Scientific Officer of the York Pharma group, responsible for identifying, acquiring and developing innovative pipeline product opportunities through to market.
From 2003 to 2011, Simon served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN). During part of this period, he was a non-executive director (and eventually deputy chairman) of Medipex, a healthcare innovation hub for NHS organisations across the Yorkshire & Humber and East Midlands regions and industry and academia internationally. Through Biomart Limited, his own consultancy company, he has provided specialist services to clients ranging from Universities, the NHS and SMEs in the healthcare, biotech and pharmaceutical sectors in respect of early stage product opportunities. Simon graduated in 1990 from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and in 1994 was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Dr Alan Warrander (Independent Non-executive Director)
Alan joined Incanthera in 2012 as a Consultant and joined the Board in 2012. He is an expert in the fields of partnering and licensing with significant experience of global pharma drug discovery and drug development processes having more than 30 years’ experience in the Pharmaceutical Industry. Alan recently retired from a part-time executive position at Oncolytics Biotech Inc. as Senior Vice President, Global Licensing and Business Development. He has also stood down as a director of Oncolytics Biotech (Barbados) Inc. and of Oncolytics Biotech (U.K.) Ltd. Until the end of 2007, he was Senior Vice President, Life Sciences at Wood Mackenzie, the global consultancy firm where he provided consultancy advice and expert scientific opinion to pharma, biotech companies, finance groups and law firms primarily in the areas of partnering, due diligence and strategic planning. Alan was also responsible for the production of a number of expert reports for a range of companies in support of AIM flotations.
Key Senior Management
Pawel Zolnierczyk (Chief Operating Officer)
Pawel joined Incanthera in January 2014. He has over 10 years’ experience in research commercialisation in the life sciences sector. He has also successfully managed IP exploitation projects toward licenses and spin-offs. A graduate of Gdansk University of Technology, Pawel has held industry appointments with CEMA Consulting including as CEO of iTech Innovations Ltd. He was formerly IP Manager for the University of Salford. Pawel has successfully negotiated deals with corporate partners including Reckitt Benckiser plc and Novartis AG. He has wide experience of managing the creation of wealth from academic IP and managing sub-contractors including the creation of Onco-NX, from DiviRNA, CarbonAir spin-offs which successfully secured seed stage investments. Before joining Incanthera, Pawel was managing director of Onco-NX which was acquired by Incanthera in 2014.
Laura Jane Brogden (Chief Financial Officer)
Laura Brogden was appointed Chief Financial Officer of Incanthera in October 2017. Laura has provided accountancy services to Incanthera for the past 6 years through her role as a senior accountant with summ.it assist LLP, a firm which provides outsourced finance staffing to companies across the UK. Laura has been with summ.it for 13 years and has extensive experience heading up the finance function for SMEs across a diverse range of industries. Laura is an Associate of the Chartered Institute of Management Accountants.
Suzanne Brocks (Head of Communications)
Suzanne joined Incanthera in April 2015 and has over 30 years City experience. Most recently as a senior director in financial and corporate communications with Buchanan Communications. Experienced in financial communications, she has advised on IPO’s and mergers and acquisitions, in addition to general financial public relations consultancy and strategic direction for a wide range of public companies. Previously Suzanne was a Relationship Manager in private banking with Hill Samuel with management of a large client portfolio in London and the Far East.